Aims and Scope

The International Journal of Molecular Oncology (IJMO) is an open-access, peer-reviewed journal designed to advance our understanding of precision oncology, genetics, and cancer biology. The magazine aims to publish high-caliber original research, critical reviews, and translational studies that explore the genetic, epigenetic, and molecular causes of cancer, from the early stages of start and progression to the response to treatment and resistance.

IJMO offers a global opportunity to present the research findings, clinicians, and industry scientists that can be used to provide genome-based diagnosis, prognosis, and individual therapy. Special emphasis is put on the research, which integrates experimental, computational, and clinical viewpoints, which is the multidisciplinary nature of today oncology research.

Our Scope

The journal aims to fill the gap between the fundamental laboratory research and the clinical practice where research findings can be replicated and new methods introduced which will enhance prevention, detection and treatment of cancer all over the world. Contributions to IJMO are welcome in any of the numerous fields of molecular and genomic oncology, such as:

  • Genomics in cancer, epigenomics, and transcriptomics.

  • Somatic and germline mutation associated with cancer formation and condition to treatment.

  • Next-generation sequencing (NGS), single-cell sequencing and multi-omics integration.

  • Tumor biology Molecular signaling pathways and regulatory networks.

  • Oncogenes, anti-oncogenes, DNA repair, and genomic instability.

  • Biomarkers, prognostic tools and companion diagnostic tools.

  • Accurate oncology and genotype-based therapeutic approaches.

  • Molecular target validation, drug resistance mechanisms and pharmacogenomics.

  • In-vitro cancer assays Cell-based assays, organoids, spheroids, and 2D/3D cultures.

  • Tumor growth, metastasis and therapeutic testing in-vivo experimental systems.

  • Applications Cancer bioinformatics, systems biology, artificial intelligence, and machine learning.

  • Molecular docking, in-silico modeling and computational simulations.

  • Translational oncology: connecting clinical treatment with test results

  • Epidemiology Genetic epidemiology Cancer susceptibility and population genomics.

  • Genomic medicine Ethical, regulatory, and data-sharing consideration.

By such a wide but narrowed purview, IJMO also promotes interdisciplinary cooperation and is open to any research that presents new procedures or proves new technology, or any study that questions current scientific suppositions.

Article Types

IJMO takes into consideration various scholarly works, such as

  • Original Research Articles

  • Review Articles

  • Translational and Clinical Investigations.

  • Methodological and Technical Reports.

  • Short Communications and Perspectives.

All submissions will be evaluated based on their originality, scientific rigor, readability, and relevance to the journal's objective

Intended Audience

The journal has a varied international audience which consists of:

  • Molecular and cellular biologists.

  • Medical researchers and clinical oncologists.

  • Genomic scientists and bioinformatics scientists.

  • Experts of translational research.

  • Professionals of precision medicine.

  • Healthcare innovators and academic theorists.

The unification of such communities through IJMO is to help promote worthwhile dialogue, speed up discoveries and help to achieve better results on cancer research and patient care across the globe.